For noninfectious diarrhea in adults living with HIV who are on ART

An antisecretory antidiarrheal that:

  • Works by normalizing water flow in the GI tract to provide symptomatic relief of diarrhea
  • Is not an opioid and does not affect GI motility

Minimally absorbed, well-tolerated, and proven to have:

  • No clinically relevant drug-drug interactions
  • No effect on viral load or CD4 counts
  • Adverse events comparable to those with placebo

Novel antidiarrheal mechanism

Mytesi blocks 2 chloride ion channels in the intestinal lumen (CFTR and CaCC)

Normalizing water flow in the GI tract—with very low risk of constipation

For noninfectious diarrhea in adults living with HIV who are on ART

Mytesi—the only treatment proven and FDA-approved for relief of diarrhea in people with HIV

Mytesi 125-mg twice daily was approved based on a randomized trial in HIV+ patients who are on stable ART and have a history of diarrhea for ≥1 month1

Results over time with Mytesi2†

Week 4 on Mytesi 125-mg BID

61% of patients had at least a
50% decrease in watery stools

Week 20 on Mytesi 125-mg BID

83% of patients had at least a
50% decrease in watery stools

Over half of patients had no watery stools at all (100% decrease)

†Daily diary data were evaluated in a supplemental analysis from all patients treated with Mytesi 125-mg BID in the ADVENT trial for up to 24 weeks. The average reduction in watery stools from baseline was determined by week.

For noninfectious diarrhea in adults living with HIV who are on ART

Information for your patients

Know when your patients have had ENOUGH...

Sometimes it's about asking the right question...

References:

  1. MacArthur R, Harkins TN, Brown SJ, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT Trial):
    A randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261–273.
  2. Data on file. Napo Pharmaceuticals, Inc.